thumbnail

Karen Gilchrist@_karengilchrist

WATCH LIVE

Key Points

  • Novo Nordisk’s ousting of its longtime CEO has bemused analysts, with many questioning the future of the Wegovy obesity drug maker.
  • “[It’s] a gigantic surprise,” analysts at Denmark’s Sydbank wrote in a note shortly after the announcement.
  • Deutsche Bank said it had “mixed feelings,” commending Novo for taking ownership for recent shortcomings, but also questioning the timing of the decision.

Boxes of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024.

Hollie Adams | Reuters

More In Deep Dives

Gen Z's wealth effect will shape the economy over time — here's who will benefit

Gen Z’s wealth effect will shape the economy over time — here’s who will benefit

Michelle Fox

The 'Make America Healthy Again' revolution has begun. Buy these food stocks to ride out the risk

The ‘Make America Healthy Again’ revolution has begun. Buy these food stocks to ride out the risk

Christina Cheddar Berk

'Physical AI' is the next frontier for the artificial intelligence cycle. How to play it

‘Physical AI’ is the next frontier for the artificial intelligence cycle. How to play it

Pia Singh

Read More